Last Updated: 04/26/16
Diagnostics Evaluation Branch (DEB)
The Diagnostics Evaluation Branch (DEB) facilitates the development of markers and validation of innovative in vitro diagnostics to improve clinical outcomes for cancer patients.
- Stimulating and supporting research to use in vitro diagnostics as prognostic markers to improve tumor classification and predictive markers to improve response to therapy.
- Stimulating and supporting research on ELSI (ethical, legal and social implications) research considerations that include, but are not limited to: (i) informed consent, (ii) data access and data security, (iii) disclosure of research findings, and (iv) promoting community engagement of research participants.
- Collaborating with other researchers and Government agencies to analytically and clinically validate in vitro diagnostics and their clinical utility.
|Tracy Lively, Ph.D.||Branch Chieffirstname.lastname@example.org||(240) 276-5944|
|Magdalena Thurin, Ph.D.||Program Directoremail@example.com||(240) 276-5973|
|Kelly Kim, Ph.D.||Program Directorfirstname.lastname@example.org||(240) 276-7811|
|Carol Weil, J.D.||Program Directoremail@example.com||(240) 276-5975|
|Lyndsay Harris, MD||Program Directorfirstname.lastname@example.org||(240) 276-6327|
|Acquilly Lionel||Administrative Supportemail@example.com||(240) 276-6005|